Dabur Pharma Ltd.

Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 22% Year-Over-Year to $2.8 billion Oncology Sales Increased 79% Year-Over-Year to $578 million FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2022. Chairman and Chief Executive Officer of Gilead Sciences, Daniel O’Day said: “This was another very strong quarter across the business. In HIV, treatment and prevention markets continue to grow with further share gains for Biktarvy in treatment, and we received our first approval for our long-acting HIV agent, lenacapavir, in Europe. In oncology, there is increasing demand for cell therapies and Trodelvy. Yescarta and Tecartus received two approvals in Europe and Trodelvy was granted FDA Priority Review for HR+/HER2- metastatic breast cancer. Overall, we are seeing terrific progress from a commercial and clinical perspective and look forward to building on this momentum.” Third Quarter 2022 Financial Results Total third quarter 2022 revenue decreased 5% to $7.0 billion compared to the same period in 2021, primarily due to lower Veklury® (remdesivir) sales, partially offset by increased sales in HIV and oncology products. Diluted Earnings Per Share (“EPS”) decreased to $1.42 for the third quarter of 2022 compared to $2.05 for the same period in 2021, mainly driven by higher acquired in-process research and development (“IPR&D”) expenses of $389 million primarily due to the acquisition of MiroBio Ltd. (“MiroBio”) and lower product gross margin and revenues, partially offset by lower income tax expense. Non-GAAP diluted EPS decreased to $1.90 for the third quarter of 2022 compared to $2.65 for the same period in 2021, primarily driven by the MiroBio acquisition, as well as lower product gross margin and revenues. As of September 30, 2022, Gilead had $6.9 billion of cash, cash equivalents and marketable debt securities down from $7.8 billion as of December 31, 2021. During the third quarter of 2022, Gilead generated $2.9 billion in operating cash flow. During the third quarter of 2022, Gilead repaid $1.0 billion of debt, made a cash payment of $414 million to acquire MiroBio, paid dividends of $928 million and repurchased $180 million of common stock. Product Sales Performance Total third quarter 2022 product sales decreased 5% to $7.0 billion compared to the same period in 2021. Total product sales, excluding Veklury, increased 11% to $6.1 billion in the third quarter of 2022 compared to the same period in 2021, primarily due to increased product sales related to HIV, cell therapy, hepatitis C virus (“HCV”) and Trodelvy® (sacituzumab govitecan-hziy). HIV product sales increased 7% to $4.5 billion in the third quarter of 2022 compared to the same period in 2021, primarily driven by favorable channel mix associated with government utilization leading to higher average realized price, as well as higher demand. Biktarvy® (bictegravir 50mg/emtricitabine 200mg (“FTC”)/tenofovir alafenamide 25mg (“TAF”)) sales increased 22% year-over-year in the third quarter of 2022, primarily due to higher demand and channel mix. Descovy® (FTC 200mg/TAF 25mg) sales increased 16% year-over-year in the third quarter of 2022, primarily driven by channel mix and higher demand, partially offset by inventory dynamics. HCV product sales increased 22% to $524 million in the third quarter of 2022 compared to the same period in 2021, primarily due to a favorable resolution of a prior year rebate claim in Europe and other favorable pricing dynamics in the United States, partially offset by fewer patient starts. Hepatitis B virus (“HBV”) and hepatitis delta virus (“HDV”) product sales increased 7% to $264 million in the third quarter of 2022 compared to the same period in 2021, primarily driven by Vemlidy® (TAF 25mg). Vemlidy sales increased 10% in the third quarter of 2022 compared to the same period in 2021, primarily driven by favorable inventory dynamics. Cell therapy product sales increased 79% to $398 million in the third quarter of 2022 compared to the same period in 2021. Yescarta® (axicabtagene ciloleucel) sales increased 81% to $317 million in the third quarter of 2022, primarily driven by demand in relapsed or refractory (“R/R”) large B-cell lymphoma (“LBCL”) in the United States and Europe. Tecartus® (brexucabtagene autoleucel) sales increased 72% to $81 million in the third quarter of 2022, primarily driven by demand in R/R mantle cell lymphoma (“MCL”) in the United States and Europe as well as in adult R/R B-cell precursor acute lymphoblastic leukemia (“ALL”) in the United States. Trodelvy sales increased by 78% to $180 million in the third quarter of 2022 compared to the same period in 2021, primarily driven by adoption in both the second- and third-line settings for the treatment of metastatic triple-negative breast cancer. Veklury sales decreased by 52% to $925 million for the third quarter of 2022 compared to the same period in 2021, primarily driven by lower rates of COVID-19 related hospitalizations compared to the third quarter of 2021. Veklury revenue generally reflects COVID-19 related rates and severity of infections and hospitalizations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19. Third Quarter 2022 Product Gross Margin, Operating Expenses and Effective Tax Rate Product gross margin was 80.0% for the third quarter of 2022 compared to 83.4% for the same period in 2021. Non-GAAP product gross margin was 86.8% for the third quarter of 2022 compared to 90.0% in the same period in 2021. The decreases were primarily driven by a favorable court decision in the third quarter of 2021 that led to the reversal of the previously recorded $175 million litigation reserve during that period, as well as Biktarvy-related royalty expense that began in the first quarter of 2022 and a change in product mix. Research and development (“R&D”) expenses for the third quarter of 2022 were $1.1 billion, relatively flat with the same period in 2021. Non-GAAP R&D expenses for the third quarter of 2022 were $1.2 billion, relatively flat with the same period in 2021(1). Acquired IPR&D expenses for the third quarter of 2022 were $448 million compared to $65 million(1) in the same period in 2021. The increase primarily reflects an expense of $389 million related to the MiroBio acquisition. Selling, general and administrative (“SG&A”) expenses for the third quarter of 2022 were $1.2 billion, relatively flat with the same period in 2021. Non-GAAP SG&A expenses for the third quarter of 2022 were $1.2 billion, relatively flat with the same period in 2021. The effective tax rate (“ETR”) for the third quarter of 2022 was 26.6% compared to 24.8% for the same period in 2021. Non-GAAP ETR for the third quarter of 2022 was 22.4% compared to 18.9% for the same period in 2021. The increases in GAAP and Non-GAAP ETR were primarily due to a non-deductible acquired IPR&D charge related to Gilead’s acquisition of MiroBio. ________________________________ (1) Beginning in the second quarter of 2022, expenses related to development milestones and other collaboration payments made prior to regulatory approval of a developed product were reclassified from R&D expenses to Acquired IPR&D expenses in the Condensed Consolidated Statements of Income. We believe this presentation assists users of the financial statements to better understand the total costs incurred to acquire IPR&D projects. Prior periods have been recast for both GAAP and Non-GAAP reporting to reflect this classification, resulting in a reduction of previously-reported R&D expenses of $46 million and $93 million for the three and nine months ended September 30, 2021, respectively, and $8 million for the three months ended March 31, 2022. Guidance and Outlook For the full-year, Gilead has updated its guidance and now expects: Total product sales between $25.9 billion and $26.2 billion, compared to $24.5 billion and $25.0 billion previously. Total product sales, excluding Veklury, between $22.5 billion to $22.8 billion, compared to $22.0 billion and $22.5 billion previously. Total Veklury sales of approximately $3.4 billion, compared to approximately $2.5 billion previously. Non-GAAP earnings per share between $6.95 and $7.15, compared to $6.35 and $6.75 previously. Earnings per share between $3.35 and $3.55, compared to $2.90 and $3.30 previously. This financial guidance excludes the impact of any expenses related to potential acquisitions or business development transactions that have not been executed, fair value adjustments of equity securities and discrete tax charges or benefits associated with changes in tax related laws and guidelines as Gilead is unable to project such amounts. A reconciliation between GAAP and non-GAAP financial information for the 2022 guidance is provided in the accompanying tables. Also see the Forward-Looking Statements described below. The financial guidance is subject to a number of risks and uncertainties, including uncertainty around the duration and magnitude of the COVID-19 pandemic. While the pandemic can be expected to continue to impact Gilead’s business and broader market dynamics, the rate and degree of these impacts as well as the corresponding recovery from the pandemic may vary across Gilead’s business. Key Updates Since Our Last Quarterly Release Virology Announced the European Commission (“EC”) has granted Marketing Authorization for Sunlenca® (lenacapavir) for the treatment of HIV infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive antiviral regimen. Announced that Merck & Co., Inc. (“Merck”) and Gilead plan to resume their Phase 2 study under an amended protocol. The study will evaluate an investigational once-weekly oral combination treatment regimen of Merck’s islatravir at a lower weekly dose and Gilead’s lenacapavir. Received a positive opinion from EMA’s Committee for Medicinal Products for Human Use (“CHMP”) to expand the indication of Biktarvy to include pediatric patients with HIV who are at least 2 years of age and weigh at least 14 kg. Received a positive opinion from EMA’s CHMP to extend the indication of Veklury for the treatment of pediatric patients under 12 years of age with COVID-19. Announced that the World Health Organization has updated its living treatment guideline to conditionally recommend Veklury for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. Demonstrated in vitro antiviral activity of Veklury against Omicron subvariants BA.2.12.1, BA.4 and BA.5, which are currently the most common circulating variants. Results confirm that Veklury retains antiviral activity against all Omicron subvariants analyzed to date. Oncology Presented results of the second interim analysis of the TROPiCS-02 study in patients with pre-treated HR+/HER2- metastatic breast cancer at the European Society for Medical Oncology meeting. The results demonstrated a statistically significant and clinically meaningful improvement in median overall survival (“OS”) as compared to chemotherapy (median OS: 14.4 months vs. 11.2 months; hazard ratio=0.79; 95% confidence interval: 0.65-0.96; p=0.02). Additionally, data from a post hoc subgroup analysis of TROPiCS-02 were presented that showed progression-free survival benefit in patients with HR+/HER2- metastatic breast cancer regardless of their HER2- status, consistent with the study’s intention-to-treat population. Announced FDA accepted for Priority Review the supplemental Biologics License Application of Trodelvy for the treatment of patients with pre-treated HR+/HER2- metastatic breast cancer. Trodelvy has not been approved by any regulatory agency for the treatment of HR+/HER2- metastatic breast cancer, and its safety and efficacy have not been established for this indication. Announced an agreement to acquire the remaining worldwide development and commercialization rights to Trodelvy from Everest Medicines in Greater China, South Korea and other Asian markets. Received European Marketing Authorization for Yescarta use in adults with second-line diffuse large B-cell lymphoma and high-grade B-cell lymphoma. Additionally, the EC granted Marketing Authorization for Tecartus for the treatment of adult R/R ALL, and in Canada, received conditional marketing authorization for Yescarta for R/R follicular lymphoma after two or more lines of systemic therapy. Received FDA approval of viral vector manufacturing facility in Oceanside, California. Granted Orphan Drug Designation by FDA for KITE-222, an investigational CAR T-cell therapy targeted at C-type lectin-like molecule-1 (CLL-1), for the treatment of acute myeloid leukemia. Announced strategic collaboration with MacroGenics, Inc. (“MacroGenics”) to develop bispecific antibodies to treat various cancers. The agreement includes an upfront payment of $60 million to MacroGenics and an exclusive option on MGD024, an investigational CD123 and CD3 bispecific antibody. Inflammation Completed the acquisition of MiroBio for $414 million in cash. MiroBio is a UK-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors. Corporate Announced that the company’s Board of Directors declared a quarterly dividend of $0.73 per share of common stock for the fourth quarter of 2022. The dividend is payable on December 29, 2022, to stockholders of record at the close of business on December 15, 2022. Future dividends will be subject to Board approval. Certain amounts and percentages in this press release may not sum or recalculate due to rounding. Conference Call At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on and will be archived on for one year. Non-GAAP Financial Information The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets and inventory step-up charges, and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables. Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (“SEC”), Gilead no longer excludes the initial costs of acquired IPR&D projects from its non-GAAP financial measures. Prior period non-GAAP financial measures are revised to conform to the new presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statements Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: the impact of the COVID-19 pandemic on Gilead’s business, financial condition and results of operations; the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury sales and Gilead’s ability to effectively manage the global supply and distribution of Veklury; Gilead’s ability to achieve its anticipated full year 2022 financial results, including as a result of potential adverse revenue impacts from COVID-19 and potential revenues from Veklury; Gilead’s ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangement with Dragonfly; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Trodelvy, Tecartus, Yescarta and bulevirtide, and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive regulatory approvals in a timely manner or at all, including FDA approval of lenacapavir for treatment of HIV-1 infection in heavily treatment-experienced people with multi-drug resistant HIV-1 infection, EC approval of lenacapavir for treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, EC approval of Veklury for the treatment of COVID-19 in adults and adolescents with pneumonia requiring supplemental oxygen and EC approval for Tecartus for the treatment of adult patients 26 years of age and above with R/R B-cell precursor ALL, and the risk that any such approvals, if granted, may be subject to significant limitations on use; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products, including the risk that Kite may be unable to increase its manufacturing capacity, timely manufacture and deliver its products or produce an amount of supply sufficient to satisfy demand for such products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products, including Yescarta; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended September 30, 2022 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements. # # # Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, HEPSERA®, JYSELECA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, SUNLENCA® , TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®. This report may also refer to trademarks, service marks and trade names of other companies. For more information on Gilead Sciences, Inc., please visit or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235). GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in millions, except per share amounts) 2022 2021 2022 2021 Revenues: Product sales $ 6,978 $ 7,356 $ 19,650 $ 19,848 Royalty, contract and other revenues 64 65 242 213 Total revenues 7,042 7,421 19,892 20,061 Costs and expenses: Cost of goods sold 1,395 1,223 4,261 3,974 Research and development expenses 1,149 1,101 3,429 3,243 Acquired in-process research and development expenses 448 65 786 270 In-process research and development impairment — — 2,700 — Selling, general and administrative expenses 1,213 1,190 3,653 3,596 Total costs and expenses 4,205 3,579 14,829 11,083 Income from operations 2,837 3,842 5,063 8,978 Interest expense (229 ) (250 ) (709 ) (763 ) Other income (expense), net (176 ) (154 ) (571 ) (696 ) Income before income taxes 2,432 3,438 3,783 7,519 Income tax expense (646 ) (852 ) (850 ) (1,694 ) Net income 1,786 2,586 2,933 5,825 Net loss attributable to noncontrolling interest 3 6 19 18 Net income attributable to Gilead $ 1,789 $ 2,592 $ 2,952 $ 5,843 Net income per share attributable to Gilead common stockholders - basic $ 1.43 $ 2.06 $ 2.35 $ 4.65 Shares used in per share calculation - basic 1,255 1,256 1,255 1,256 Net income per share attributable to Gilead common stockholders - diluted $ 1.42 $ 2.05 $ 2.34 $ 4.63 Shares used in per share calculation - diluted 1,261 1,262 1,261 1,262 Cash dividends declared per share $ 0.73 $ 0.71 $ 2.19 $ 2.13 Product gross margin 80.0 % 83.4 % 78.3 % 80.0 % Research and development expenses as a % of revenues 16.3 % 14.8 % 17.2 % 16.2 % Selling, general and administrative expenses as a % of revenues 17.2 % 16.0 % 18.4 % 17.9 % Operating margin 40.3 % 51.8 % 25.5 % 44.8 % Effective tax rate 26.6 % 24.8 % 22.5 % 22.5 % GILEAD SCIENCES, INC. TOTAL REVENUE SUMMARY (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in millions, except percentages) 2022 2021 Change 2022 2021 Change Product sales: HIV $ 4,487 $ 4,189 7% $ 12,422 $ 11,777 5% HCV 524 429 22% 1,371 1,488 (8)% HBV/HDV 264 247 7% 733 704 4% Cell therapy 398 222 79% 1,040 632 65% Trodelvy 180 101 78% 485 262 85% Other 200 245 (18)% 693 777 (11)% Total product sales excluding Veklury 6,053 5,433 11% 16,745 15,640 7% Veklury 925 1,923 (52)% 2,905 4,208 (31)% Total product sales 6,978 7,356 (5)% 19,650 19,848 (1)% Royalty, contract and other revenues 64 65 (1)% 242 213 14% Total revenues $ 7,042 $ 7,421 (5)% $ 19,892 $ 20,061 (1)% GILEAD SCIENCES, INC. NON-GAAP FINANCIAL INFORMATION(1) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in millions, except percentages) 2022 2021 Change 2022 2021 Change Non-GAAP: Cost of goods sold $ 923 $ 736 25% $ 2,634 $ 2,427 9% Research and development expenses $ 1,173 $ 1,063 10% $ 3,425 $ 3,149 9% Acquired IPR&D expenses $ 448 $ 65 NM $ 786 $ 270 NM Selling, general and administrative expenses $ 1,212 $ 1,178 3% $ 3,566 $ 3,332 7% Other income (expense), net $ 20 $ (12 ) NM $ 25 $ (29 ) NM Diluted EPS $ 1.90 $ 2.65 (28)% $ 5.59 $ 6.50 (14)% Product gross margin 86.8 % 90.0 % -323 bps 86.6 % 87.8 % -121 bps Research and development expenses as a % of revenues 16.7 % 14.3 % 236 bps 17.2 % 15.7 % 152 bps Selling, general and administrative expenses as a % of revenues 17.2 % 15.9 % 131 bps 17.9 % 16.6 % 133 bps Operating margin 46.7 % 59.0 % -1234 bps 47.7 % 54.2 % -654 bps Effective tax rate 22.4 % 18.9 % 350 bps 20.1 % 18.9 % 120 bps ________________________________ NM - Not Meaningful (1) Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 10 - 11. Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission, the Company no longer excludes the initial costs of acquired IPR&D projects from its non-GAAP financial measures. Prior period non-GAAP financial measures are revised to conform to the new presentation. GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in millions, except percentages and per share amounts) 2022 2021 2022 2021 Cost of goods sold reconciliation: GAAP cost of goods sold $ 1,395 $ 1,223 $ 4,261 $ 3,974 Acquisition-related – amortization of acquired intangibles and inventory step-up charges (472 ) (487 ) (1,585 ) (1,547 ) Other(1) — — (42 ) — Non-GAAP cost of goods sold $ 923 $ 736 $ 2,634 $ 2,427 Product gross margin reconciliation: GAAP product gross margin 80.0 % 83.4 % 78.3 % 80.0 % Acquisition-related – amortization of acquired intangibles and inventory step-up charges 6.8 % 6.6 % 8.1 % 7.8 % Other(1) — % — % 0.2 % — % Non-GAAP product gross margin 86.8 % 90.0 % 86.6 % 87.8 % Research and development expenses reconciliation: GAAP research and development expenses $ 1,149 $ 1,101 $ 3,429 $ 3,243 Acquisition-related – amortization of acquired intangibles and inventory step-up charges — . (67 ) — (67 ) Acquisition-related – other costs(2) 24 (2 ) 13 (14 ) Other(1) — 31 (18 ) (13 ) Non-GAAP research and development expenses $ 1,173 $ 1,063 $ 3,425 $ 3,149 IPR&D impairment reconciliation: GAAP IPR&D impairment $ — $ — $ 2,700 $ — IPR&D impairment — — (2,700 ) — Non-GAAP IPR&D impairment $ — $ — $ — $ — Selling, general and administrative expenses reconciliation: GAAP selling, general and administrative expenses $ 1,213 $ 1,190 $ 3,653 $ 3,596 Acquisition-related – other costs(2) (2 ) (10 ) (2 ) (42 ) Other(1) 1 (2 ) (84 ) (222 ) Non-GAAP selling, general and administrative expenses $ 1,212 $ 1,178 $ 3,566 $ 3,332 Income from operations reconciliation: GAAP income from operations $ 2,836 $ 3,842 $ 5,063 $ 8,978 Acquisition-related – amortization of acquired intangibles and inventory step-up charges 472 554 1,585 1,614 Acquisition-related – other costs(2) (22 ) 12 (11 ) 56 IPR&D impairment — — 2,700 — Other(1) (1 ) (29 ) 144 235 Non-GAAP income from operations $ 3,286 $ 4,379 $ 9,480 $ 10,883 Operating margin reconciliation: GAAP operating margin 40.3 % 51.8 % 25.5 % 44.8 % Acquisition-related – amortization of acquired intangibles and inventory step-up charges 6.7 % 7.5 % 8.0 % 8.0 % Acquisition-related – other costs(2) (0.3 )% 0.2 % (0.1 )% 0.3 % IPR&D impairment — % — % 13.6 % — % Other(1) — % (0.7 )% 0.7 % 1.1 % Non-GAAP operating margin 46.7 % 59.0 % 47.7 % 54.2 % Other income (expense), net reconciliation: GAAP other income (expense), net $ (176 ) $ (154 ) $ (571 ) $ (696 ) Loss from equity securities, net 197 142 596 667 Non-GAAP other income (expense), net $ 20 $ (12 ) $ 25 $ (29 ) GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in millions, except percentages and per share amounts) 2022 2021 2022 2021 Effective tax rate reconciliation: GAAP effective tax rate 26.6 % 24.8 % 22.5 % 22.5 % Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(3) (4.1 )% (5.8 )% (2.4 )% (3.5 )% Non-GAAP effective tax rate 22.4 % 18.9 % 20.1 % 18.9 % Net income attributable to Gilead reconciliation: GAAP net income attributable to Gilead $ 1,789 $ 2,592 $ 2,952 $ 5,843 Acquisition-related – amortization of acquired intangibles and inventory step-up charges 379 446 1,264 1,301 Acquisition-related – other costs(2) (23 ) 9 (13 ) 46 IPR&D impairment — — 2,057 — Other(1) — (23 ) 104 143 Loss from equity securities, net 198 154 570 687 Discrete and related tax charges(3) 49 165 118 179 Non-GAAP net income attributable to Gilead $ 2,391 $ 3,343 $ 7,052 $ 8,199 Diluted EPS reconciliation: GAAP diluted EPS $ 1.42 $ 2.05 $ 2.34 $ 4.63 Acquisition-related – amortization of acquired intangibles and inventory step-up charges 0.30 0.35 1.00 1.03 Acquisition-related – other costs(2) (0.02 ) 0.01 (0.01 ) 0.04 IPR&D impairment — — 1.63 — Other(1) — (0.01 ) 0.08 0.12 Loss from equity securities, net 0.16 0.12 0.45 0.54 Discrete and related tax charges(3) 0.04 0.13 0.09 0.14 Non-GAAP diluted EPS $ 1.90 $ 2.65 $ 5.59 $ 6.50 Non-GAAP adjustment summary: Cost of goods sold adjustments $ 472 $ 487 $ 1,627 $ 1,547 Research and development expenses adjustments (24 ) 38 5 94 IPR&D impairment adjustments — — 2,700 — Selling, general and administrative expenses adjustments 1 12 86 264 Total non-GAAP adjustments before other income (expense), net, and income taxes 450 537 4,418 1,905 Other income (expense), net, adjustments 197 142 596 667 Total non-GAAP adjustments before income taxes 646 679 5,014 2,572 Income tax effect of non-GAAP adjustments above (93 ) (93 ) (1,032 ) (395 ) Discrete and related tax charges(3) 49 165 118 179 Total non-GAAP adjustments after tax $ 602 $ 751 $ 4,100 $ 2,356 ______________________________ (1) Adjustments to Cost of goods sold and Research and development expenses primarily include various restructuring expenses during the first quarter of 2022 and the second quarter of 2021. Adjustments to Selling, general and administrative expenses primarily include donations to the Gilead Foundation, a California nonprofit organization, during the second quarters of 2022 and 2021. (2) Adjustments include employee-related expenses, contingent consideration fair value adjustments and other expenses associated with Gilead’s acquisitions of MiroBio, Ltd., Immunomedics, Inc. and MYR GmbH. (3) Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States. GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP 2022 FULL-YEAR GUIDANCE(1) (unaudited) (in millions, except percentages and per share amounts) Provided February 1, 2022 Updated April 28, 2022 Updated August 2, 2022 Updated October 27, 2022 Projected product gross margin GAAP to non-GAAP reconciliation: GAAP projected product gross margin 76% - 77% 76% - 77% 76% - 77% 78% - 79% Acquisition-related and other ~ 9% ~ 9% ~ 9% ~ 8% Non-GAAP projected product gross margin 85% - 86% 85% - 86% 85% - 86% 86% - 87% Projected income from operations GAAP to non-GAAP reconciliation: GAAP projected income from operations $8,600 - $9,400 $5,800 - $6,600 $6,050 - $6,650 $6,900 - $7,300 Acquisition-related, IPR&D impairment and other ~ 2,100 ~ 4,900 ~ 4,950 ~ 4,900 Non-GAAP projected income from operations $10,700 - $11,500 $10,700 - $11,500 $11,000 - $11,600 $11,800 - $12,200 Projected effective tax rate GAAP to non-GAAP reconciliation: GAAP projected effective tax rate ~ 22% ~ 20% ~ 21% ~ 22% Discrete and related tax adjustments, and income tax effect of adjustments above and fair value adjustments of equity securities ~ 2% —% ~ 1% ~ 2% Non-GAAP projected effective tax rate ~ 20% ~ 20% ~ 20% ~ 20% Projected diluted EPS GAAP to non-GAAP reconciliation: GAAP projected diluted EPS $4.70 - $5.20 $3.00- $3.50 $2.90 - $3.30 $3.35 - $3.55 Acquisition-related, IPR&D impairment, fair value adjustments of equity securities, other and discrete and related tax adjustments ~ 1.50 ~ 3.20 ~ 3.45 ~ 3.60 Non-GAAP projected diluted EPS $6.20 - $6.70 $6.20 - $6.70 $6.35 - $6.75 $6.95 - $7.15 ________________________________ (1) The non-GAAP 2022 full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States. Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) September 30, December 31, (in millions) 2022 2021 Assets Cash, cash equivalents and marketable securities $ 6,942 $ 7,829 Accounts receivable, net 4,354 4,493 Inventories 2,602 2,734 Property, plant and equipment, net 5,349 5,121 Intangible assets, net 29,440 33,455 Goodwill 8,314 8,332 Other assets 5,556 5,988 Total assets $ 62,557 $ 67,952 Liabilities and Stockholders’ Equity Current liabilities $ 10,423 $ 11,610 Long-term liabilities 31,077 35,278 Stockholders’ equity(1) 21,057 21,064 Total liabilities and stockholders’ equity $ 62,557 $ 67,952 ________________________________ (1) As of September 30, 2022 and December 31, 2021, there were 1,254 shares of common stock issued and outstanding, respectively. GILEAD SCIENCES, INC. SELECTED CASH FLOW INFORMATION (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2022 2021 2022 2021 Net cash provided by operating activities $ 2,863 $ 3,253 $ 6,505 $ 8,179 Net cash used in investing activities (713 ) (234 ) (2,091 ) (2,853 ) Net cash used in financing activities (2,118 ) (3,527 ) (4,915 ) (6,935 ) Effect of exchange rate changes on cash and cash equivalents (72 ) (23 ) (138 ) (26 ) Net change in cash and cash equivalents (40 ) (531 ) (639 ) (1,635 ) Cash and cash equivalents at beginning of period 4,739 4,893 5,338 5,997 Cash and cash equivalents at end of period $ 4,699 $ 4,362 $ 4,699 $ 4,362 Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2022 2021 2022 2021 Net cash provided by operating activities $ 2,863 $ 3,253 $ 6,505 $ 8,179 Capital expenditures (157 ) (139 ) (547 ) (423 ) Free cash flow(1) $ 2,706 $ 3,114 $ 5,958 $ 7,756 ________________________________ (1) Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above. GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2022 2021 2022 2021 HIV Biktarvy – U.S. $ 2,286 $ 1,875 $ 6,088 $ 4,926 Biktarvy – Europe 278 254 807 707 Biktarvy – Other International 201 147 577 461 2,766 2,276 7,472 6,094 Complera / Eviplera – U.S. 20 28 56 73 Complera / Eviplera – Europe 21 31 76 104 Complera / Eviplera – Other International 3 5 10 12 43 64 142 189 Descovy – U.S. 444 355 1,152 994 Descovy – Europe 28 42 92 128 Descovy – Other International 28 36 91 105 500 433 1,335 1,227 Genvoya – U.S. 502 576 1,441 1,633 Genvoya – Europe 71 100 220 306 Genvoya – Other International 27 68 103 184 600 744 1,764 2,123 Odefsey – U.S. 276 275 763 773 Odefsey – Europe 86 112 278 336 Odefsey – Other International 12 12 36 39 374 399 1,077 1,148 Stribild – U.S. 22 28 68 94 Stribild – Europe 7 11 23 33 Stribild – Other International 3 3 7 12 32 42 98 139 Truvada – U.S. 24 55 77 268 Truvada – Europe 3 5 12 18 Truvada – Other International 2 7 13 24 30 67 102 310 Revenue share – Symtuza(1) – U.S. 85 86 251 261 Revenue share – Symtuza(1) – Europe 40 41 126 125 Revenue share – Symtuza(1) – Other International 4 3 10 8 130 130 388 394 Other HIV(2) – U.S. 1 24 11 110 Other HIV(2) – Europe 6 6 20 19 Other HIV(2) – Other International 5 4 15 24 12 34 45 153 Total HIV – U.S. 3,661 3,302 9,906 9,132 Total HIV – Europe 541 602 1,653 1,776 Total HIV – Other International 285 285 863 869 4,487 4,189 12,422 11,777 GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY - (Continued) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2022 2021 2022 2021 Veklury Veklury – U.S. 336 1,527 1,179 2,763 Veklury – Europe 130 109 560 761 Veklury – Other International 458 287 1,166 684 925 1,923 2,905 4,208 HCV Ledipasvir / Sofosbuvir(3) – U.S. 8 14 27 63 Ledipasvir / Sofosbuvir(3) – Europe 5 5 13 24 Ledipasvir / Sofosbuvir(3) – Other International 12 26 43 76 25 45 83 163 Sofosbuvir / Velpatasvir(4) – U.S. 241 173 629 649 Sofosbuvir / Velpatasvir(4) – Europe 131 77 288 234 Sofosbuvir / Velpatasvir(4) – Other International 84 82 244 272 455 332 1,161 1,155 Other HCV(5) – U.S. 34 37 88 97 Other HCV(5) – Europe 7 12 31 64 Other HCV(5) – Other International 2 3 7 9 44 52 127 170 Total HCV – U.S. 283 224 745 809 Total HCV – Europe 143 94 332 322 Total HCV – Other International 98 111 294 357 524 429 1,371 1,488 HBV/HDV Vemlidy – U.S. 129 103 306 266 Vemlidy – Europe 9 9 27 25 Vemlidy – Other International 90 96 289 298 228 208 622 589 Viread – U.S. 2 1 4 8 Viread – Europe 5 7 17 22 Viread – Other International 15 18 48 55 22 26 69 85 Other HBV/HDV(6) – U.S. — — 1 1 Other HBV/HDV(6) – Europe 13 13 41 29 14 13 42 30 Total HBV/HDV – U.S. 131 104 311 275 Total HBV/HDV – Europe 28 29 85 76 Total HBV/HDV – Other International 106 114 337 353 264 247 733 704 Cell therapy Tecartus – U.S. 60 35 160 94 Tecartus – Europe 20 12 56 25 Tecartus – Other International 1 — 2 — 81 47 217 119 Yescarta – U.S. 210 100 528 300 Yescarta – Europe 91 66 253 188 Yescarta – Other International 16 9 42 25 317 175 823 513 Total cell therapy – U.S. 270 135 688 394 Total cell therapy – Europe 111 78 308 213 Total cell therapy – Other International 17 9 44 25 398 222 1,040 632 GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY - (Continued) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2022 2021 2022 2021 Trodelvy Trodelvy – U.S. 139 100 379 261 Trodelvy– Europe 38 1 98 1 Trodelvy – Other International 3 — 8 — 180 101 485 262 Other AmBisome – U.S. 9 7 48 32 AmBisome – Europe 63 67 192 202 AmBisome – Other International 33 69 140 186 105 143 380 420 Letairis – U.S. 43 46 135 157 Other(7) – U.S. 28 34 91 109 Other(7) – Europe 11 17 52 68 Other(7) – Other International 13 5 35 23 52 56 178 200 Total other – U.S. 80 87 275 298 Total other – Europe 75 84 244 270 Total other – Other International 46 74 174 209 200 245 693 777 Total product sales – U.S. 4,900 5,479 13,482 13,932 Total product sales – Europe 1,064 997 3,281 3,419 Total product sales – Other International 1,013 880 2,887 2,497 $ 6,978 $ 7,356 $ 19,650 $ 19,848 _______________________________ (1) Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company. (2) Includes Atripla, Emtriva and Tybost. (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC. (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC. (5) Includes Vosevi and Sovaldi. (6) Includes Hepcludex and Hepsera. (7) Includes Cayston, Jyseleca, Ranexa and Zydelig.

Biktarvy Sales Increased 28% Year-Over-Year to $2.6 billion Oncology Sales Increased 71% Year-Over-Year to $527 million FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2022. “This was a very strong quarter for Gilead, with solid commercial and clinical execution,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “Excluding Veklury, product sales grew 7% year-over-year. There was continued strong demand for our HIV portfolio with further share growth for Biktarvy, and oncology revenues reached an all-time high, driven by cell therapy and Trodelvy.” Second Quarter 2022 Financial Results Total second quarter 2022 revenue increased 1% to $6.3 billion compared to the same period in 2021, primarily due to increased sales in HIV and oncology products, offset partially by decreased sales of Veklury® (remdesivir) and hepatitis C virus (“HCV”) products. Diluted Earnings Per Share (“EPS”) decreased to $0.91 for the second quarter of 2022 compared to $1.21 for the same period in 2021. The decrease was primarily due to higher acquired in-process research & development (“IPR&D”) expenses from an upfront payment of $300 million, or $0.18 on a post-tax per share basis, related to the Dragonfly Therapeutics, Inc. (“Dragonfly”) collaboration and higher net unrealized losses from our strategic equity investments. Non-GAAP diluted EPS decreased 13% to $1.58 for the second quarter of 2022 compared to $1.81(1) for the same period in 2021, primarily reflecting the Dragonfly upfront payment and Biktarvy® (bictegravir 50mg/emtricitabine 200mg (“FTC”)/tenofovir alafenamide 25mg (“TAF”))-related royalty expense that began in the first quarter of 2022, offset partially by higher revenues. As of June 30, 2022, Gilead had $7.0 billion of cash, cash equivalents and marketable debt securities down from $7.8 billion as of December 31, 2021 primarily due to payment associated with the settlement of the bictegravir-related litigation, paid dividends, acquired IPR&D payments related to collaborations, debt repayments, stock repurchases and capital expenditures, partially offset by net cash provided by operations. During the second quarter of 2022, Gilead generated $1.8 billion in operating cash flow. During the second quarter of 2022, Gilead made a $300 million collaboration upfront payment to Dragonfly, paid dividends of $920 million and repurchased $72 million of common stock. ___________________________________ (1) Non-GAAP diluted EPS has been recast due to an update to our non-GAAP policy in the first quarter 2022, resulting in a $0.06 reduction of previously-reported non-GAAP diluted EPS for the second quarter 2021. Refer to Non-GAAP Financial Information section below for further information. Product Sales Performance Total second quarter 2022 product sales were $6.1 billion, flat compared to the same period in 2021. Total product sales, excluding Veklury, increased 7% to $5.7 billion in the second quarter of 2022 compared to the same period in 2021, primarily due to growth in the HIV, Cell Therapy and Trodelvy® (sacituzumab govitecan-hziy) businesses, offset partially by declining revenue in HCV. HIV product sales increased 7% to $4.2 billion in the second quarter of 2022 compared to the same period in 2021, primarily reflecting changes in channel mix leading to higher average realized price as well as higher demand for treatment and pre-exposure prophylaxis (“PrEP”) medicines. Biktarvy sales increased 28% year-over-year in the second quarter of 2022, primarily due to higher demand and channel mix. Descovy® (FTC 200mg/TAF 25mg) sales increased 6% year-over-year in the second quarter of 2022, primarily driven by channel mix and increased demand, partially offset by inventory dynamics. HCV product sales decreased 18% to $448 million in the second quarter of 2022 compared to the same period in 2021, primarily driven by channel mix leading to lower average realized price and fewer patient starts. Hepatitis B virus (“HBV”) and hepatitis delta virus (“HDV”) product sales decreased 1% to $234 million in the second quarter of 2022 compared to the same period in 2021. Vemlidy® (TAF 25mg) sales decreased 3% in the second quarter of 2022 compared to the same period in 2021, primarily driven by China Volume Based Procurement update, offset in part by volume growth in all other regions. Cell therapy product sales increased 68% to $368 million in the second quarter of 2022 compared to the same period in 2021. Yescarta® (axicabtagene ciloleucel) sales increased 66% to $295 million in the second quarter of 2022, primarily driven by demand for relapsed or refractory (“R/R”) large B-cell lymphoma (“LBCL”) in the United States and Europe and R/R follicular lymphoma (“FL”) in the United States. Tecartus® (brexucabtagene autoleucel) sales increased 78% to $73 million in the second quarter of 2022, primarily driven by demand for R/R mantle cell lymphoma (“MCL”) in the United States and Europe and for adult patients with R/R B-cell precursor acute lymphoblastic leukemia (“ALL”) in the United States. Trodelvy sales increased by 79% to $159 million in the second quarter of 2022 compared to the same period in 2021, primarily reflecting adoption in both the second- and third-line settings for the treatment of metastatic triple-negative breast cancer (“TNBC”) in the United States and Europe as well as for metastatic urothelial cancer in the United States. Veklury sales decreased by 46% to $445 million for the second quarter of 2022 compared to the same period in 2021. Veklury revenue generally reflects COVID-19 related rates and severity of infections and hospitalizations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19. Second Quarter 2022 Product Gross Margin, Operating Expenses and Effective Tax Rate Product gross margin was 76.5% for the second quarter of 2022 compared to 77.4% for the same period in 2021. Non-GAAP product gross margin was 85.6% for the second quarter of 2022 compared to 86.4% in the same period in 2021. The decreases were primarily driven by Biktarvy-related royalty expense that began in the first quarter of 2022. Research and development (“R&D”) expenses for the second quarter of 2022 were $1.1 billion, relatively flat with the same period in 2021. Non-GAAP R&D expenses for the second quarter of 2022 were $1.1 billion compared to $1.0 billion(2) in the same period in 2021. GAAP and Non-GAAP R&D expenses primarily reflect increased investment in development activities and timing of clinical trial activities, primarily for oncology. GAAP R&D expenses were offset by lower restructuring expenses as compared to the prior year. Acquired IPR&D expenses for the second quarter of 2022 were $330 million compared to $138 million(2) in the same period in 2021. The increase primarily reflects an upfront payment related to the Dragonfly collaboration. Selling, general and administrative (“SG&A”) expenses for the second quarter of 2022 were $1.4 billion, relatively flat with the same period in 2021. Non-GAAP SG&A expenses for the second quarter of 2022 were $1.3 billion compared to $1.1 billion in the same period in 2021. GAAP and Non-GAAP SG&A expenses primarily reflect increased promotional and marketing investment, including for Trodelvy, as well as higher corporate activities, including information technology projects and grants. GAAP SG&A expenses were offset by lower donations to Gilead Foundation as compared to the prior year. The effective tax rate (“ETR”) for the second quarter of 2022 was 24.5% compared to 16.5% for the same period in 2021, primarily due to a discrete tax benefit related to an intra-entity transfer of intangible assets in the three months ended June 30, 2021, and higher net unrealized losses from equity investments that are non-deductible for income tax purposes. Non-GAAP ETR for the second quarter of 2022 was 19.3% compared to 19.5% for the same period in 2021. ___________________________________ (2) Beginning in the second quarter of 2022, expenses related to development milestones and other collaboration payments made prior to regulatory approval of a developed product were reclassified from R&D expenses to Acquired IPR&D expenses in the Condensed Consolidated Statements of Income. We believe this presentation assists users of the financial statements to better understand the total costs incurred to acquire IPR&D projects. Prior periods have been recast for both GAAP and Non-GAAP reporting to reflect this classification, resulting in a reduction of previously-reported R&D expenses of $42 million and $47 million for the three and six months ended June 30, 2021, respectively, and $8 million for the three months ended March 31, 2022. Guidance and Outlook For the full-year, Gilead has updated its guidance and now expects: Total product sales between $24.5 billion and $25.0 billion, compared to $23.8 billion and $24.3 billion previously. Total product sales, excluding Veklury, between $22.0 billion to $22.5 billion, compared to $21.8 billion and $22.3 billion previously. Total Veklury sales of approximately $2.5 billion, compared to approximately $2.0 billion previously. Non-GAAP earnings per share between $6.35 and $6.75, compared to $6.20 and $6.70 previously. Earnings per share between $2.90 and $3.30, compared to $3.00 and $3.50 previously. This financial guidance excludes the impact of any expenses related to potential acquisitions or business development transactions that have not been executed, fair value adjustments of equity securities and discrete tax charges or benefits associated with changes in tax related laws and guidelines as Gilead is unable to project such amounts. A reconciliation between GAAP and non-GAAP financial information for the 2022 guidance is provided in the accompanying tables. Also see the Forward-Looking Statements described below. The financial guidance is subject to a number of risks and uncertainties, including uncertainty around the duration and magnitude of the COVID-19 pandemic. While the pandemic can be expected to continue to impact Gilead’s business and broader market dynamics, the rate and degree of these impacts as well as the corresponding recovery from the pandemic may vary across Gilead’s business. Key Updates Since Our Last Quarterly Release Virology Announced FDA lifted the clinical hold placed on the Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and pre-exposure prophylaxis following the agency’s review of the storage and compatibility data of lenacapavir injection with an alternate vial made from aluminosilicate glass. Announced FDA accepted for review the New Drug Application resubmission for investigational lenacapavir for the treatment of HIV-1 infection in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. FDA has assigned a Prescription Drug User Fee Act date of December 27, 2022. Received a positive opinion from the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) for investigational lenacapavir for the treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. Presented data at the International AIDS Conference, which included Week 48 data from the Phase 3 ALLIANCE trial evaluating Biktarvy in adults with HIV/HBV coinfection. Results from ALLIANCE showed that Biktarvy had superior HBV DNA suppression over the comparator dolutegravir/FTC/TDF, with both antiretroviral regimens similarly achieving high rates of HIV suppression. Additionally, five-year data from two Phase 3 trials of Biktarvy as first-line therapy in people living with HIV further demonstrated Biktarvy’s sustained efficacy, safety pro high barrier to resistance. Presented Week 48 results for the pivotal Phase 3 MYR301 trial of bulevirtide for the treatment of chronic HDV at the International Liver Congress 2022. The study met its primary endpoint, achieving statistically significant combined response rates (virologic and biochemical responses) with bulevirtide. Responses increased from Week 24 to Week 48, highlighting an improved response with prolonged treatment. The safety pro consistent with prior reports. Announced a new Joint Procurement Agreement for Veklury for participating member states across the European Union and the European Economic Area. Received a positive opinion from EMA’s CHMP for Veklury to be granted full marketing authorization for the treatment of COVID-19 in adults and adolescents with pneumonia requiring supplemental oxygen and adults who do not require supplemental oxygen and are at increased risk of developing severe COVID-19. Oncology Presented results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy versus physicians’ choice of chemotherapy (“TPC”) in heavily pre-treated patients with HR+/HER2- metastatic breast cancer at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. Announced final data from the Phase 3 ASCENT trial of Trodelvy in second-line and later metastatic TNBC at ASCO, reinforcing Trodelvy’s survival benefit over TPC in this patient population. Received updated NCCN recommendations for sacituzumab govitecan-hziy to a category 1 preferred recommendation in second-line and later metastatic TNBC and was added as a category 2A preferred recommendation in the investigational indication of HR+/HER2- advanced breast cancer by the NCCN Guidelines® for Breast Cancer. Category 1 is the highest recommendation by NCCN, indicating that based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. The use of Trodelvy in patients with HR+/HER2- breast cancer is investigational, and Trodelvy has not been approved by FDA for this use. Highlighted Yescarta and Tecartus data at ASCO that included findings from a subanalysis of ZUMA-7, real-world outcomes and long-term follow-ups. Real-world data for Yescarta showed consistent survival and safety data regardless of race and ethnicity, and in a ZUMA-7 subanalysis, demonstrated an over eight-fold greater median event-free survival and clinically meaningful improvements in quality of life as compared to standard of care. For Tecartus, long-term data suggested durable responses were induced in patients with R/R MCL and in adult patients with R/R ALL. Announced approval of Yescarta by the European Commission for the treatment of R/R FL. Received a positive opinion from EMA’s CHMP for Tecartus for the treatment of adult patients 26 years of age and above with R/R B-cell precursor ALL. Announced FDA lifted the remaining partial clinical hold on studies evaluating magrolimab as a potential treatment for lymphoma and multiple myeloma. Entered into a strategic research collaboration with Dragonfly to advance a number of novel natural killer (“NK”) cell engager-based immunotherapies for oncology and inflammation indications. Under the agreement, Gilead will receive an exclusive worldwide license to investigational DF7001 and have options to license several additional NK cell engager programs. Corporate Announced that the company’s Board of Directors declared a quarterly dividend of $0.73 per share of common stock for the third quarter of 2022. The dividend is payable on September 29, 2022, to stockholders of record at the close of business on September 15, 2022. Future dividends will be subject to Board approval. Appointed Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing effective July 2022. Appointed Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel effective August 2022. Announced an $85 million contribution to the Gilead Foundation. Certain amounts and percentages in this press release may not sum or recalculate due to rounding. Conference Call At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on and will be archived on for one year. Non-GAAP Financial Information The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets and inventory step-up charges, and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities and discrete and related tax charges or benefits associated with changes in tax related laws and guidelines. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables. Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (“SEC”), Gilead no longer excludes the initial costs of acquired IPR&D projects from its non-GAAP financial measures. Prior period non-GAAP financial measures are revised to conform to the new presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statements Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: the impact of the COVID-19 pandemic on Gilead’s business, financial condition and results of operations; the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury sales and Gilead’s ability to effectively manage the global supply and distribution of Veklury; Gilead’s ability to achieve its anticipated full year 2022 financial results, including as a result of potential adverse revenue impacts from COVID-19 and potential revenues from Veklury; Gilead’s ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangement with Dragonfly; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Trodelvy, Tecartus, Yescarta and bulevirtide, and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive regulatory approvals in a timely manner or at all, including FDA approval of lenacapavir for treatment of HIV-1 infection in heavily treatment-experienced people with multi-drug resistant HIV-1 infection, EC approval of lenacapavir for treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, EC approval of Veklury for the treatment of COVID-19 in adults and adolescents with pneumonia requiring supplemental oxygen and EC approval for Tecartus for the treatment of adult patients 26 years of age and above with R/R B-cell precursor ALL, and the risk that any such approvals, if granted, may be subject to significant limitations on use; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products, including the risk that Kite may be unable to increase its manufacturing capacity, timely manufacture and deliver its products or produce an amount of supply sufficient to satisfy demand for such products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products, including Yescarta; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended June 30, 2022 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements. # # # Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX® (BULEVIRTIDE), HEPSERA®, JYSELECA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA® and ZYDELIG®. This report may also refer to trademarks, service marks and trade names of other companies. For more information on Gilead Sciences, Inc., please visit or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235). GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions, except per share amounts) 2022 2021 2022 2021 Revenues: Product sales $ 6,138 $ 6,152 $ 12,672 $ 12,492 Royalty, contract and other revenues 122 65 178 148 Total revenues 6,260 6,217 12,850 12,640 Costs and expenses: Cost of goods sold 1,442 1,390 2,866 2,751 Research and development expenses 1,102 1,092 2,280 2,142 Acquired in-process research and development expenses 330 138 338 205 In-process research and development impairment — — 2,700 — Selling, general and administrative expenses 1,357 1,351 2,440 2,406 Total costs and expenses 4,231 3,971 10,624 7,504 Income from operations 2,029 2,246 2,226 5,136 Interest expense (242 ) (256 ) (480 ) (513 ) Other income (expense), net (284 ) (173 ) (395 ) (542 ) Income before income taxes 1,503 1,817 1,351 4,081 Income tax expense (368 ) (300 ) (204 ) (842 ) Net income 1,135 1,517 1,147 3,239 Net loss attributable to noncontrolling interest 9 5 16 12 Net income attributable to Gilead $ 1,144 $ 1,522 $ 1,163 $ 3,251 Net income per share attributable to Gilead common stockholders - basic $ 0.91 $ 1.21 $ 0.93 $ 2.59 Shares used in per share calculation - basic 1,256 1,255 1,255 1,256 Net income per share attributable to Gilead common stockholders - diluted $ 0.91 $ 1.21 $ 0.92 $ 2.58 Shares used in per share calculation - diluted 1,260 1,260 1,261 1,261 Cash dividends declared per share $ 0.73 $ 0.71 $ 1.46 $ 1.42 Product gross margin 76.5 % 77.4 % 77.4 % 78.0 % Research and development expenses as a % of revenues 17.6 % 17.6 % 17.7 % 16.9 % Selling, general and administrative expenses as a % of revenues 21.7 % 21.7 % 19.0 % 19.0 % Operating margin 32.4 % 36.1 % 17.3 % 40.6 % Effective tax rate 24.5 % 16.5 % 15.1 % 20.6 % GILEAD SCIENCES, INC. TOTAL REVENUE SUMMARY (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions, except percentages) 2022 2021 Change 2022 2021 Change Product sales: HIV $ 4,228 $ 3,938 7 % $ 7,935 $ 7,588 5 % HCV 448 549 (18 )% 847 1,059 (20 )% HBV/HDV 234 237 (1 )% 470 457 3 % Cell therapy 368 219 68 % 642 410 57 % Trodelvy 159 89 79 % 305 161 90 % Other 256 291 (12 )% 493 532 (7 )% Total product sales excluding Veklury 5,693 5,323 7 % 10,692 10,207 5 % Veklury 445 829 (46 )% 1,980 2,285 (13 )% Total product sales 6,138 6,152 — % 12,672 12,492 1 % Royalty, contract and other revenues 122 65 87 % 178 148 20 % Total revenues $ 6,260 $ 6,217 1 % $ 12,850 $ 12,640 2 % GILEAD SCIENCES, INC. NON-GAAP FINANCIAL INFORMATION(1) (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions, except percentages) 2022 2021 Change 2022 2021 Change Non-GAAP: Cost of goods sold $ 886 $ 836 6 % $ 1,711 $ 1,691 1 % Research and development expenses $ 1,102 $ 1,042 6 % $ 2,251 $ 2,086 8 % Acquired IPR&D expenses $ 330 $ 138 139 % $ 338 $ 205 65 % Selling, general and administrative expenses $ 1,272 $ 1,121 13 % $ 2,355 $ 2,154 9 % Other income (expense), net $ 20 $ 1 NM $ 5 $ (17 ) NM Diluted EPS $ 1.58 $ 1.81 (13 )% $ 3.70 $ 3.85 (4 )% Product gross margin 85.6 % 86.4 % -83 bps 86.5 % 86.5 % -0 bps Research and development expenses as a % of revenues 17.6 % 16.8 % 81 bps 17.5 % 16.5 % 102 bps Selling, general and administrative expenses as a % of revenues 20.3 % 18.0 % 232 bps 18.3 % 17.0 % 132 bps Operating margin 42.7 % 49.5 % -684 bps 48.2 % 51.5 % -329 bps Effective tax rate 19.3 % 19.5 % -20 bps 18.8 % 18.9 % -10 bps ________________________________ NM - Not Meaningful (1) Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 11 - 12. Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission, the Company no longer excludes the initial costs of acquired IPR&D projects from its non-GAAP financial measures. Prior period non-GAAP financial measures are revised to conform to the new presentation. GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions, except percentages and per share amounts) 2022 2021 2022 2021 Cost of goods sold reconciliation: GAAP cost of goods sold $ 1,442 $ 1,390 $ 2,866 $ 2,751 Acquisition-related – amortization of acquired intangibles and inventory step-up charges (556 ) (554 ) (1,113 ) (1,060 ) Other(1) — — (42 ) — Non-GAAP cost of goods sold $ 886 $ 836 $ 1,711 $ 1,691 Product gross margin reconciliation: GAAP product gross margin 76.5 % 77.4 % 77.4 % 78.0 % Acquisition-related – amortization of acquired intangibles and inventory step-up charges 9.1 % 9.0 % 8.8 % 8.5 % Other(1) — % — % 0.3 % — % Non-GAAP product gross margin 85.6 % 86.4 % 86.5 % 86.5 % Research and development expenses reconciliation: GAAP research and development expenses $ 1,102 $ 1,092 $ 2,280 $ 2,142 Acquisition-related – other costs(2) — (6 ) (11 ) (12 ) Other(1) — (44 ) (18 ) (44 ) Non-GAAP research and development expenses $ 1,102 $ 1,042 $ 2,251 $ 2,086 IPR&D impairment reconciliation: GAAP IPR&D impairment $ — $ — $ 2,700 $ — IPR&D impairment — — (2,700 ) — Non-GAAP IPR&D impairment $ — $ — $ — $ — Selling, general and administrative expenses reconciliation: GAAP selling, general and administrative expenses $ 1,357 $ 1,351 $ 2,440 $ 2,406 Acquisition-related – other costs(2) — (10 ) — (32 ) Other(1) (85 ) (220 ) (85 ) (220 ) Non-GAAP selling, general and administrative expenses $ 1,272 $ 1,121 $ 2,355 $ 2,154 Income from operations reconciliation: GAAP income from operations $ 2,029 $ 2,246 $ 2,226 $ 5,136 Acquisition-related – amortization of acquired intangibles and inventory step-up charges 556 554 1,113 1,060 Acquisition-related – other costs(2) — 16 11 44 IPR&D impairment — — 2,700 — Other(1) 85 264 145 264 Non-GAAP income from operations $ 2,670 $ 3,080 $ 6,195 $ 6,504 Operating margin reconciliation: GAAP operating margin 32.4 % 36.1 % 17.3 % 40.6 % Acquisition-related – amortization of acquired intangibles and inventory step-up charges 8.9 % 8.9 % 8.7 % 8.4 % Acquisition-related – other costs(2) — % 0.3 % 0.1 % 0.3 % IPR&D impairment — % — % 21.0 % — % Other(1) 1.4 % 4.2 % 1.1 % 2.1 % Non-GAAP operating margin 42.7 % 49.5 % 48.2 % 51.5 % Other income (expense), net reconciliation: GAAP other income (expense), net $ (284 ) $ (173 ) $ (395 ) $ (542 ) Loss from equity securities, net 303 174 399 525 Non-GAAP other income (expense), net $ 20 $ 1 $ 5 $ (17 ) GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued) (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions, except percentages and per share amounts) 2022 2021 2022 2021 Effective tax rate reconciliation: GAAP effective tax rate 24.5 % 16.5 % 15.1 % 20.6 % Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments(3) (5.2 ) % 3.0 % 3.7 % (1.7 ) % Non-GAAP effective tax rate 19.3 % 19.5 % 18.8 % 18.9 % Net income attributable to Gilead reconciliation: GAAP net income attributable to Gilead $ 1,144 $ 1,522 $ 1,163 $ 3,251 Acquisition-related – amortization of acquired intangibles and inventory step-up charges 442 446 885 855 Acquisition-related – other costs(2) — 15 11 37 IPR&D impairment — — 2,057 — Other(1) 59 166 104 166 Loss from equity securities, net 308 169 372 533 Discrete and related tax charges(3) 31 (40 ) 68 14 Non-GAAP net income attributable to Gilead $ 1,985 $ 2,278 $ 4,661 $ 4,856 Diluted EPS reconciliation: GAAP diluted EPS $ 0.91 $ 1.21 $ 0.92 $ 2.58 Acquisition-related – amortization of acquired intangibles and inventory step-up charges 0.35 0.35 0.70 0.68 Acquisition-related – other costs(2) — 0.01 0.01 0.03 IPR&D impairment — — 1.63 — Other(1) 0.05 0.13 0.08 0.13 Loss from equity securities, net 0.24 0.13 0.30 0.42 Discrete and related tax charges(3) 0.02 (0.03 ) 0.05 0.01 Non-GAAP diluted EPS $ 1.58 $ 1.81 $ 3.70 $ 3.85 Non-GAAP adjustment summary: Cost of goods sold adjustments $ 556 $ 554 $ 1,155 $ 1,060 Research and development expenses adjustments — 50 29 56 IPR&D impairment adjustments — — 2,700 — Selling, general and administrative expenses adjustments 85 230 85 252 Total non-GAAP adjustments before other income (expense), net, and income taxes 641 834 3,968 1,368 Other income (expense), net, adjustments 303 174 399 525 Total non-GAAP adjustments before income taxes 945 1,008 4,368 1,893 Income tax effect of non-GAAP adjustments above (135 ) (212 ) (938 ) (302 ) Discrete and related tax charges(3) 31 (40 ) 68 14 Total non-GAAP adjustments after tax $ 841 $ 756 $ 3,498 $ 1,605 ______________________________ (1) Adjustments to Cost of goods sold and Research and development expenses include various restructuring expenses during the first quarter of 2022 and the second quarter of 2021. Adjustments to Selling, general and administrative expenses include donations to the Gilead Foundation, a California nonprofit organization, during the second quarters of 2022 and 2021. (2) Primarily includes employee-related expenses, contingent consideration fair value adjustments and other expenses associated with Gilead’s acquisitions of Immunomedics, Inc. and MYR GmbH. (3) Represents discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States. GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP 2022 FULL-YEAR GUIDANCE(1) (unaudited) (in millions, except percentages and per share amounts) Provided February 1, 2022 Updated April 28, 2022 Updated August 2, 2022 Projected product gross margin GAAP to non-GAAP reconciliation: GAAP projected product gross margin 76% - 77% 76% - 77% 76% - 77% Acquisition-related and other ~ 9% ~ 9% ~ 9% Non-GAAP projected product gross margin 85% - 86% 85% - 86% 85% - $86% Projected income from operations GAAP to non-GAAP reconciliation: GAAP projected income from operations $8,600 - $9,400 $5,800 - $6,600 $6,050 - $6,650 Acquisition-related, IPR&D impairment and other ~ 2,100 ~ 4,900 ~ 4,950 Non-GAAP projected income from operations $10,700 - $11,500 $10,700 - $11,500 $11,000 - $11,600 Projected effective tax rate GAAP to non-GAAP reconciliation: GAAP projected effective tax rate ~ 22% ~ 20% ~ 21% Discrete and related tax adjustments, and income tax effect of adjustments above and fair value adjustments of equity securities ~ 2% —% ~ 1% Non-GAAP projected effective tax rate ~ 20% ~ 20% ~ 20% Projected diluted EPS GAAP to non-GAAP reconciliation: GAAP projected diluted EPS $4.70 - $5.20 $3.00- $3.50 $2.90 - $3.30 Acquisition-related, IPR&D impairment, fair value adjustments of equity securities, other and discrete and related tax adjustments ~ 1.50 ~ 3.20 ~ 3.45 Non-GAAP projected diluted EPS $6.20 - $6.70 $6.20 - $6.70 $6.35 - $6.75 ________________________________ (1) The non-GAAP 2022 full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with acquired intangible assets and transfers of intangible assets from a foreign subsidiary to Ireland and the United States. Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) June 30, December 31, (in millions) 2022 2021 Assets Cash, cash equivalents and marketable securities $ 7,000 $ 7,829 Accounts receivable, net 4,118 4,493 Inventories 2,587 2,734 Property, plant and equipment, net 5,299 5,121 Intangible assets, net 29,885 33,455 Goodwill 8,314 8,332 Other assets 5,667 5,988 Total assets $ 62,870 $ 67,952 Liabilities and Stockholders’ Equity Current liabilities $ 9,220 $ 11,610 Long-term liabilities 33,435 35,278 Stockholders’ equity(1) 20,215 21,064 Total liabilities and stockholders’ equity $ 62,870 $ 67,952 ________________________________ (1) As of June 30, 2022 and December 31, 2021, there were 1,254 shares of common stock issued and outstanding, respectively. GILEAD SCIENCES, INC. SELECTED CASH FLOW INFORMATION (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions) 2022 2021 2022 2021 Net cash provided by operating activities $ 1,802 $ 2,316 $ 3,642 $ 4,926 Net cash used in investing activities (308 ) (577 ) (1,378 ) (2,619 ) Net cash used in financing activities (1,003 ) (931 ) (2,797 ) (3,408 ) Effect of exchange rate changes on cash and cash equivalents (48 ) 20 (66 ) (3 ) Net change in cash and cash equivalents 443 828 (599 ) (1,104 ) Cash and cash equivalents at beginning of period 4,296 4,065 5,338 5,997 Cash and cash equivalents at end of period $ 4,739 $ 4,893 $ 4,739 $ 4,893 Three Months Ended Six Months Ended June 30, June 30, (in millions) 2022 2021 2022 2021 Net cash provided by operating activities $ 1,802 $ 2,316 $ 3,642 $ 4,926 Capital expenditures (143 ) (119 ) (390 ) (284 ) Free cash flow(1) $ 1,659 $ 2,197 $ 3,252 $ 4,642 ________________________________ (1) Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above. GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions) 2022 2021 2022 2021 HIV Biktarvy – U.S. $ 2,095 $ 1,586 $ 3,801 $ 3,051 Biktarvy – Europe 268 237 529 453 Biktarvy – Other International 193 171 376 314 2,556 1,994 4,707 3,818 Descovy – U.S. 397 357 708 639 Descovy – Europe 32 44 64 86 Descovy – Other International 32 34 63 69 460 435 834 794 Genvoya – U.S. 482 551 939 1,057 Genvoya – Europe 72 100 149 206 Genvoya – Other International 29 55 76 116 582 706 1,164 1,379 Odefsey – U.S. 255 258 487 498 Odefsey – Europe 97 111 193 224 Odefsey – Other International 12 13 23 27 364 382 703 749 Revenue share – Symtuza(1) – U.S. 80 86 166 175 Revenue share – Symtuza(1) – Europe 42 40 86 84 Revenue share – Symtuza(1) – Other International 4 3 6 5 126 129 258 264 Complera / Eviplera – U.S. 20 20 37 45 Complera / Eviplera – Europe 31 39 55 73 Complera / Eviplera – Other International 3 3 7 7 54 62 99 125 Stribild – U.S. 24 35 46 66 Stribild – Europe 8 11 16 22 Stribild – Other International 2 5 5 9 33 51 66 97 Truvada – U.S. 24 94 52 213 Truvada – Europe 5 6 9 13 Truvada – Other International 5 8 11 17 34 108 72 243 Other HIV(2) – U.S. 5 57 10 86 Other HIV(2) – Europe 9 8 13 13 Other HIV(2) – Other International 4 6 9 20 18 71 33 119 Total HIV – U.S. 3,383 3,044 6,245 5,830 Total HIV – Europe 562 596 1,112 1,174 Total HIV – Other International 282 298 577 584 4,228 3,938 7,935 7,588 GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY - (Continued) (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions) 2022 2021 2022 2021 HCV Ledipasvir / Sofosbuvir(3) – U.S. 6 30 19 49 Ledipasvir / Sofosbuvir(3) – Europe 4 3 8 19 Ledipasvir / Sofosbuvir(3) – Other International 13 29 31 50 23 62 58 118 Sofosbuvir / Velpatasvir(4) – U.S. 227 262 389 476 Sofosbuvir / Velpatasvir(4) – Europe 75 82 157 157 Sofosbuvir / Velpatasvir(4) – Other International 74 98 159 190 376 442 706 823 Other HCV(5) – U.S. 30 35 54 60 Other HCV(5) – Europe 16 8 24 52 Other HCV(5) – Other International 3 2 5 6 49 45 83 118 Total HCV – U.S. 263 327 462 585 Total HCV – Europe 94 93 189 228 Total HCV – Other International 91 129 196 246 448 549 847 1,059 HBV/HDV Vemlidy – U.S. 97 86 177 163 Vemlidy – Europe 9 8 18 16 Vemlidy – Other International 89 106 199 202 195 200 394 381 Viread – U.S. 3 3 3 7 Viread – Europe 6 8 12 15 Viread – Other International 15 17 32 37 24 28 47 59 Other HBV/HDV(6) – U.S. — 1 — 1 Other HBV/HDV(6) – Europe 15 8 28 16 16 9 28 17 Total HBV/HDV – U.S. 100 90 180 171 Total HBV/HDV – Europe 30 24 57 47 Total HBV/HDV – Other International 104 123 232 239 234 237 470 457 Veklury Veklury – U.S. 41 416 843 1,236 Veklury – Europe 126 264 430 652 Veklury – Other International 278 149 708 397 445 829 1,980 2,285 Cell therapy Tecartus – U.S. 53 32 100 59 Tecartus – Europe 20 9 35 13 Tecartus – Other International — — 1 — 73 41 136 72 Yescarta – U.S. 193 108 318 200 Yescarta – Europe 85 61 162 122 Yescarta – Other International 17 9 26 16 295 178 506 338 Total cell therapy – U.S. 246 140 418 259 Total cell therapy – Europe 105 70 197 135 Total cell therapy – Other International 17 9 27 16 368 219 642 410 GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY - (Continued) (unaudited) Three Months Ended Six Months Ended June 30, June 30, (in millions) 2022 2021 2022 2021 Trodelvy Trodelvy – U.S. 120 89 240 161 Trodelvy– Europe 35 — 61 — Trodelvy – Other International 3 — 5 — 159 89 305 161 Other AmBisome – U.S. 15 13 40 25 AmBisome – Europe 63 69 129 135 AmBisome – Other International 54 74 107 117 132 156 275 277 Letairis – U.S. 49 57 92 111 Other(7) – U.S. 37 37 63 75 Other(7) – Europe 26 31 41 51 Other(7) – Other International 13 10 22 18 76 78 125 144 Total other – U.S. 101 107 195 211 Total other – Europe 88 100 169 186 Total other – Other International 67 84 129 135 256 291 493 532 Total product sales – U.S. 4,254 4,213 8,582 8,453 Total product sales – Europe 1,042 1,147 2,216 2,422 Total product sales – Other International 842 792 1,873 1,617 $ 6,138 $ 6,152 $ 12,672 $ 12,492 _______________________________ (1) Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company. (2) Includes Atripla, Emtriva and Tybost. (3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC. (4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC. (5) Includes Vosevi and Sovaldi. (6) Includes Hepcludex and Hepsera. (7) Includes Cayston, Jyseleca, Ranexa and Zydelig.